AirAvant Medical is a research-oriented, privately held company that focuses on developing and marketing innovative respiratory medical devices to treat obstructive sleep apnea and other breathing disorders. AirAvant has recently launched the Bongo® Rx, a groundbreaking EPAP device that is FDA-cleared to treat mild to moderate obstructive sleep apnea.
Holding numerous patents with several patents pending, AirAvant Medical continues to innovate revolutionary respiratory technologies for the sleep-disorder breathing market, which includes Obstructive Sleep Apnea, snoring, and COPD applications.
AirAvant Medical was founded by Bruce Sher, Shara Hernandez, Javier Collazo, and Ron Richard in 2013. The company’s founders were former executives at InnoMed Technologies, Inc., where they had developed and launched a highly acclaimed line of respiratory and sleep devices, including the Nasal-Aire, the Hybrid, and the Aloha CPAP interfaces. In 2019, AirAvant Medical introduced its flagship product – the Bongo® Rx.
AirAvant Medical’s mission is to improve health and welfare by creating user-centered, non-surgical medical devices that treat respiratory disorders while minimizing impact to the patient’s lifestyle.
With the Bongo Rx, AirAvant Medical aims to transform the sleep apnea market by meeting the need for a more discreet and less encumbering solution than other therapies commonly prescribed today. AirAvant is working to ensure that patients in the U.S. and Canada can easily purchase the Bongo Rx, and plans on expanding availability to other countries.
Our company will continue developing cutting-edge respiratory medical devices to meet the demand for user-friendly design and effective treatment in the sleep-disorder breathing market. AirAvant Medical is committed to delivering innovative products, high product quality, and excellent customer service.